Impact of hemophilia treatment on the management of HIV disease

S. V. Seremetis, A. N. Phillips, M. S. Saag, N. Rubini, L. M. Aledort, P. M. Mannucci

Research output: Contribution to journalArticle

Abstract

In summary, in HIV+ persons with severe hemophilia A, the use of very high-purity (monoclonally purified) factor VIII concentrates was associated with stabilization of absolute CD4+ cell counts over 3 years. The use of intermediate-purity concentrates (specific activity ≤50 U/mg) was associated with deterioration of absolute CD4+ cell counts over time. However, there was a statistically significant difference in time to two consecutive CD4+ cell counts + cell count will result in improved clinical outcome. These data provide a rationale for selecting very high-purity factor VIII for HIV+ hemophiliacs.

Original languageEnglish
JournalAIDS Patient Care
Volume8
Issue numberSUPPL. 1
Publication statusPublished - 1994

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Leadership and Management

Fingerprint Dive into the research topics of 'Impact of hemophilia treatment on the management of HIV disease'. Together they form a unique fingerprint.

  • Cite this

    Seremetis, S. V., Phillips, A. N., Saag, M. S., Rubini, N., Aledort, L. M., & Mannucci, P. M. (1994). Impact of hemophilia treatment on the management of HIV disease. AIDS Patient Care, 8(SUPPL. 1).